3 AI Healthcare Stocks Retail Investors Are Watching In Australia

Artificial intelligence healthcare stocks sit at the crossroads of powerful themes that investors are watching closely today. Central banks, inflation trends, and shifting credit conditions are moving capital toward areas where data, efficiency, and research matter most. AI in healthcare aims to improve diagnostics, cut waste, and support more personalised treatment using massive data sets. The Transformative AI Healthcare Stocks screener focuses on companies linked to these themes and filters for opportunities within this focused area. In this article, you will see three stocks from the screener to consider for further research.

ImExHS (ASX:IME)

Overview: ImExHS is a Sydney based healthcare technology company that provides cloud based medical imaging software and outsourced radiology services, helping hospitals and clinics manage radiology, cardiology and pathology images and reports. Its AQUILA, ALULA and ANTEROS platforms sit alongside teleradiology and diagnostic services that supply both images and radiologist interpretations.

Operations: ImExHS generates most of its revenue from A$10.0 million in Software and A$19.2 million in Radiology services, with virtually all revenue currently coming from Latin America at about A$29.0 million.

Market Cap: A$15.1 million

ImExHS gives you exposure to AI enabled imaging software and radiology services in one company, with a focus on Latin American healthcare systems that creates both potential opportunity and concentration risk. Analysts have noted the company is currently loss making and funded entirely by higher risk external borrowing, so execution on any shift toward profitable recurring software revenue will be important to monitor. The stock trades on a low P/S compared with healthcare peers, which may appeal to value focused investors who are comfortable with early stage profitability and governance questions, especially after recent finance and company secretary changes in 2026 that could influence how the situation evolves.

ImExHS combines a low P/S ratio with Latin America focused radiology and AI imaging that many investors may be overlooking. Get the full picture with the analysis report for ImExHS and see what could shift sentiment next.

Singular Health Group (ASX:SHG)

Overview: Singular Health Group is an Australian medical technology company that turns standard 2D medical scans into interactive 3D models to help doctors and patients better visualise anatomy for diagnosis and treatment planning. It also offers tools for secure image sharing, collaboration, and cloud based AI analysis.

Operations: Singular Health Group generates about A$1.0 million in revenue from the provision and development of medical technology, with reported sales primarily linked to the United States at around A$0.5 million.

Market Cap: A$64.1 million

Singular Health Group provides targeted exposure to AI assisted 3D medical imaging, a segment that aims to make diagnostics faster and more accurate. The company is currently unprofitable, with a declining earnings trend, less than one year of cash runway and 100% of liabilities funded through higher risk external borrowing, indicating clear execution and funding risk. At the same time, experienced and largely independent board oversight, progress on regulatory clearances, pilots and hospital collaborations, and the potential for recurring software licensing or contract renewals mean that changes in commercial traction or capital support could affect how the market views this stock.

Singular Health Group’s 3D imaging story is still early, yet pressure from losses and limited cash runway could be masking what matters most. Get the full context in the 4 warning signs (3 are major!) before the next twist emerges.

Artrya (ASX:AYA)

Overview: Artrya is a West Perth based medical technology company that builds AI driven, cloud based software to detect and assess coronary artery disease from CCTA heart scans. The technology helps clinicians identify plaque, anatomy and blood flow issues that may put patients at risk of a heart attack.

Operations: Artrya currently reports A$0.03 million in revenue from the development of its AI driven CCTA image analysis technology, all generated in Australia.

Market Cap: A$813.4 million

Artrya positions investors at the centre of AI in cardiac imaging, with its Salix platform targeting subscription and fee per scan revenue as CCTA usage and reimbursement for plaque assessment spread across major US insurers. Analysts expect strong revenue and earnings growth over the coming years, supported by a large SAPPHIRE trial and a balance sheet that includes about A$76.5 million in cash, no debt and an anticipated A$5.6 million R&D rebate. At the same time, Artrya is still loss making, dependent on very low current receipts and facing competition from established cardiac imaging tools, with ongoing insider selling and dilution that are important to monitor. The key consideration for investors is how these strengths and pressure points fit together in the broader context of Artrya’s business.

Artrya’s strong cash position and limited current revenue provide substantial scope for the company’s story to develop. Get the analyst forecasts for Artrya and see how one key risk could change the narrative.

The three AI healthcare stocks in this article are just a starting point. The full Transformative Artificial intelligence (AI) Healthcare Stocks screener surfaces five more companies that carry similarly compelling stories around diagnostics, treatment personalisation, efficiency, and remote care. Use Simply Wall St to identify and analyze the specific catalysts, cash profiles, and clinical or regulatory milestones that matter most so you can focus on the highest conviction ideas in this space.

Take Control of Your Investment Journey

If Singular Health Group or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Fresh Alternatives Before They Fly

Fresh stock ideas can move from quiet to flying once momentum catches on. Use these curated screens while it matters, before the crowd closes the gap, and consider entering positions earlier in the trend.

• Spot potential early movers in niche sectors by scanning 12 high quality undiscovered gems. These are currently under the radar and have fundamentals that appear stronger than many headline stocks.
• Explore potential resilience when markets wobble by reviewing 9 resilient stocks with low risk scores to see which companies currently pair lower risk scores with balance sheets built for persistence.
• Follow structural shifts in data and processing by checking 56 AI infrastructure stocks, which focuses on the picks and shovels of AI rather than headline software stories.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com